Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Quick facts
Marketed products
- Amlodipine/Atorvastatin · Cardiovascular
This combination drug reduces blood pressure by blocking calcium channels in blood vessels and lowers cholesterol by inhibiting HMG-CoA reductase. - Atorvastatin and Omega-3 fatty acids
- Blood samples for the analysis of sildenafil in plasma
- Detrol LA · Urology
Detrol LA is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary muscle contractions and urinary urgency. - Diclofenac + Omeprazole · Rheumatology / Gastroenterology
Diclofenac inhibits prostaglandin synthesis to reduce inflammation and pain, while omeprazole suppresses gastric acid production to protect against NSAID-induced ulcers. - Doxazosin mysylate GITS · Cardiovascular; Urology
Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure. - Ibuprofen plus Omeprazole · Pain management / Gastroenterology
Ibuprofen reduces inflammation and pain by inhibiting cyclooxygenase enzymes, while omeprazole protects the stomach by suppressing gastric acid production. - iso- 5 - mononitrate · Cardiovascular
Isosorbide 5-mononitrate is a nitrate vasodilator that releases nitric oxide to relax vascular smooth muscle and improve blood flow. - latanoprost 0.005% ophthalmic solution
- Lyrica (pregabalin) · Neurology; Pain Management; Psychiatry
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. - Non-selective NSAIDS · Pain Management, Rheumatology, Cardiovascular
Non-selective NSAIDs inhibit both COX-1 and COX-2 enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation, pain, and fever. - Oxybutynin ER · Urology / Neurology
Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity. - Placebo and celecoxib · Rheumatology / Pain Management
Celecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of prostaglandins that mediate inflammation and pain. - pregabalin and celecoxib
- tolterodine SR, overactive bladder
- Travoprost 004% sterile ophthalmic solution · Ophthalmology
Travoprost is a prostaglandin F analog that binds to prostaglandin F (FP) receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. - Viagra (sildenafil citrate) · Urology / Cardiovascular
Sildenafil inhibits phosphodiesterase type 5 (PDE5), allowing cyclic GMP to accumulate and promote smooth muscle relaxation in the corpus cavernosum, increasing blood flow to the penis. - Xalacom · Other
- Xalatan · Cardiovascular
- ziprazidone · Other
- Zoloft tablets · Psychiatry / Neurology
Zoloft selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Phase 3 pipeline
- celecoxib and ibuprofen SR
- fixed combination latanoprost-timolol · Ophthalmology
Latanoprost-timolol is a fixed combination of a prostaglandin analog and a beta-blocker that works by reducing intraocular pressure in the eye. - Geodon (Ziprasidone) · Psychiatry
Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. - Intramuscular ziprasidone mesylate · Psychiatry
Ziprasidone is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. - iv sildenafil · Urology
Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor that works by increasing blood flow to the penis to treat erectile dysfunction. - placebo and pregabalin · Pain, Anxiety
Pregabalin is a structural analog of the neurotransmitter gamma-aminobutyric acid (GABA) and acts as a GABA receptor agonist. - Placebo matched with pregabalin · Neurology
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. - Pregabalin add-on therapy · Neurology
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. - Pregabalin Dose Level 1 · Neurology; Pain Management; Psychiatry
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. - Pregabalin Dose Level 2 · Neurology; Pain Management; Psychiatry
Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. - sildenafil citrate (UK-92,480)
- unfixed Latanoprost and Timolol · Ophthalmology
Latanoprost is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production.
Phase 2 pipeline
Phase 1 pipeline
- alprazolam sublingual tablet
- Amlodipine ODT - test
- Amlodipine - reference
- Atorvastatin pediatric appropriate formulation
- Atorvastatin pediatric formulation
- B16 Fasted
- B16 Fed
- celecoxib reference formulation
- celecoxib test formulation A1
- celecoxib test formulation B2
- celecoxib test formulation C1
- Commercial tablet with water
- Eletriptan commercial tablet
- Epamin · Other
- Epamin: Reference Drug
- Formulation D ODT tablet 50 mg
- JZoloft
- Nicergoline from China
- Nicergoline from Italy
- ODT #1 with water
- ODT #1 without water
- ODT #2 with water
- ODT #2 without water
- Sequence 2 - Treatment D: Controlled Release Pregabalin
- Sequence 4 - Treatment A: Controlled Release Pregabalin
- Sequence 4 - Treatment B: Controlled Release Pregabalin
- sertraline ODT
- Sildenafil ODT
- Test formulation D1
- Test formulation D2
- Test formulation D3
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: